Stockreport

Clinical Results for BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Demonstrated Superior Immune Profile Compared to Neulasta®

BeyondSpring, Inc. - Ordinary Shares  (BYSI) 
Last beyondspring, inc. - ordinary shares earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.beyondspringpharma.com
PDF Company to Present Latest Findings at 2018 Society for Immunotherapy of Cancer’s (SITC) Annual Meeting NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. ( [Read more]